Anton Gokin/LinkedIn
Sep 2, 2025, 20:50
Anton Gokin: Latest Updates in Oncology Market and Science
Anton Gokin, Scientific and Business Insights Expert at BostonGene, shared a post on LinkedIn:
“Latest Updates in Oncology Market and Science!
- TOLREMO therapeutics gets two FDA Fast Track designations for TT125-802 (CBP/p300 inhibitor) for pretreated, advanced NSCLC with EGFR or KRAS G12C mutations.
- D3 Bio receives FDA Breakthrough Therapy Designation for D3S-001 (KRAS G12C inhibitor) for pretreated metastatic NSCLC and Orphan Drug Designation for KRAS G12C-mutated CRC.
R and D and Trial Results
- Eli Lilly and Company announced that Verzenio (CDK4/6i) showed a statistically significant and clinically meaningful OS benefit in the monarchE Ph3 trial for high-risk, HR+, HER2- early breast cancer.
- Merck and Daiichi Sankyo initiated a Ph3 trial of patritumab deruxtecan (HER3-directed ADC) for metastatic HR+, HER2- breast cancer.
- Akeso Biopharma ivonescimab (bispecific PD-1/VEGF Ab) showed a ‘clinically meaningful’ OS benefit in its Ph3 HARMONi-A trial for EGFR-mutated NSCLC.
- PDS Biotechnology PDS0101 (a T-cell immunoth) + Keytruda showed 39.3 mo median OS in Ph2 HNSCC, significantly improving on SoC.
- BeOne Medicines reports positive topline Ph1/2 data for sonrotoclax (BCL2 inhibitor) in r/r MCL, paving the way for accelerated approval
- Elicera Therapeutics AB reports active lymphoma eliminated in 4/6 patients, Phase I/IIa study of ELC-301 (iTANK-armed CAR T-cell therapy) for B-cell lymphoma.
- Antegenes reported positive results from its Ph1/2 programs, ATG-022 (CLDN18.2 ADC) in gastric cancer and ATG-037 (CD73 inhibitor) in CPI-resistant melanoma and NSCLC.
- Marker Therapeutics, Inc.. reports encouraging Ph1 APOLLO data for MT-601 (MAR-T cell therapy) in relapsed lymphoma with high ORRs.
Finance and Investment
- BeOne Medicines sells ex-China royalties on Amgen’s Imdelltra (bispecific T-cell engager) toRoyalty Pharmaa for an upfront payment of $885M, accelerating value from the SCLC drug.
- Wugen secured a $115M equity financing round to advance its allogeneic CAR-T therapy, WU-CART-007, for T-cell malignancies.
- Incyclix Bio secured an $11.25M Series B extension to complete its Ph1/2 trial for INX-315 (CDK2i) in CDK4/6i-resistant ER+/HER2- BC.
Partnerships and Deals
- Immuneering Corporation and Eli Lilly and Company partner to evaluate IMM-1-104 (MEK inhibitor) with Lilly’s olomorasib (KRAS G12C inhibitor) in a planned Ph2 trial for KRAS G12C-mutant NSCLC.
- Appia Bio, a cell therapy company and former Kite Pharma collaborator, is shutting down after failing to secure further funding needed to advance its platform into the clinic.
- Northwest Biotherapeutics will acquire Advent Bioservices, securing manufacturing capabilities for its late-stage DCVax-L (dendritic cell therapy) to treat glioblastoma.
Follow me for future updates!”
Advent Bioservices
Akeso Biopharma
Amgen
Antegenes
Anton Gokin
Appia Bio
BeOne Medicines
BostonGene
cancer
D3 Bio
Daiichi Sankyo
Eli Lilly and Company
Elicera Therapeutics
FDA
Immuneering Corporation
Inc
Incyclix Bio
Kite Pharma
Marker Therapeutics
Merck
Northwest Biotherapeutics
OncoDaily
Oncology
PDS Biotechnology
TOLREMO therapeutics
Wugen
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41